10:01 AM EDT, 06/13/2025 (MT Newswires) -- Enliven Therapeutics ( ELVN ) said Friday it has priced its previously announced underwritten public offering of about 8.4 million of its common shares at $19.66 apiece and pre-funded warrants to buy up to about 1.8 million of its common shares at roughly $19.66 per pre-funded warrant for gross proceeds of about $200 million.

The company said it intends to close the offering around Monday, and has granted the underwriters a 30-day option to buy up to an additional 1.5 million of its common shares at the public offering price.

Enliven's stock was up 3.1% in recent Friday trading.

Price: 20.27, Change: +0.61, Percent Change: +3.10